Retreatment With Nivolumab in Patients With R/R Classical Hodgkin Lymphoma After Discontinuation of the Therapy With Immune Checkpoint Inhibitors

Hematological Oncology - United Kingdom
doi 10.1002/hon.176_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Retreatment With Immune Checkpoint Inhibitors in Solid Tumors: A Systematic Review

2020English

A First-In-Human Trial of the Novel Multi-Action Therapy Tinostamustine (Edo-S101) in Patients With Relapsed/Refractory (R/R) Hodgkin Lymphoma (Hl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Concurrent Therapy With Immune Checkpoint Inhibitors and TNFα Blockade in Patients With Gastrointestinal Immune-Related Adverse Events

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements Towards New Perspectives

Journal of Oncology
Oncology
2019English

Recurrent Pneumonitis in Patients With Melanoma Treated With Immune Checkpoint Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2019English

Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

REAL-WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) OF CLASSICAL HODGKIN LYMPHOMA (cHL) PATIENTS (PTS) TREATED WITH ANTI-PD1 CHECKPOINT INHIBITORS IN THE UNITED STATES (US)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy